
VJHemOnc Podcast iwAL 2022 Session I: the standard of care in AML in 2022
Oct 28, 2022
Mark Levis, A leading expert in AML research and treatment, discusses the standard of care in AML in 2022, including the role of transplantation and novel agents and treatment approaches for relapsed FLT3-mutated disease. Transplant benefits and considerations, BMTCTN trial analysis, and treatment considerations based on age and fitness level are also discussed. Stem cell transplants and targeted therapies are explored, emphasizing the importance of collaboration between leukemia and transplant physicians.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Transplant and the Role in Treating AML
02:54 • 5min
Debate between Rick and Mac, BMTCTN trial analysis, and the role of myeloblation
07:42 • 2min
Treatment considerations for AML patients based on age and fitness level
09:19 • 2min
Stem Cell Transplants and Targeted Therapies
10:57 • 6min
